Does the intraoperative tranexamic acid decrease operative blood loss during posterior spinal fusion for treatment of adolescent idiopathic scoliosis?

Mitsuru Yagi, Jun Hasegawa, Narihito Nagoshi, Shingo Iizuka, Shinjiro Kaneko, Kentaro Fukuda, Masakazu Takemitsu, Masanobu Shioda, Masafumi MacHida

Research output: Contribution to journalArticle

60 Citations (Scopus)

Abstract

STUDY DESIGN. Retrospective, observational study. OBJECTIVE. To assess the efficacy and safety of tranexamic acid (TXA) in decreasing operative blood loss and the need for transfusion during posterior spinal fusion for the treatment of idiopathic scoliosis in adolescents. SUMMARY OF BACKGROUND DATA.: Blood loss associated with spinal surgery is a common potential cause of morbidity and often requires a blood transfusion, which subjects patients to the known risks of blood transfusion including transmission of diseases. Since the 1990s, intraoperative administration of antifibrinolytics has gained popularity. This study assesses the efficacy and safety of TXA in controlling blood loss during posterior spinal fusion for the treatment of idiopathic scoliosis in adolescents at 1 institution. METHODS. A retrospective comparative analysis of 106 consecutive adolescents undergoing posterior spinal fusion procedures at 1 institution was performed. Patients were analyzed according to treatment group: controls (63) and TXA (43). There were no significant differences in demographic (age, sex, and comorbidities) or surgical traits (surgical time, number of fused vertebrae, preoperative hematocrit and hemoglobin) between the 2 groups. RESULTS. TXA group had significantly less intraoperative blood loss (613 ± 195 mL) than the control group (1079 ± 421 mL; P < 0.001) as well as postoperative blood loss (155 ± 86 mL and 263 ± 105 mL, respectively; P < 0.001). TXA group received significantly less blood during the surgical procedure than the control group (258 ± 246 mL and 377 ± 200 mL, respectively; P < 0.001). There were no major intraoperative complications for any of the treatment groups. CONCLUSION. TXA treatment group lost significantly less blood and received significantly fewer blood transfusions than the control group without significant differences in intra- and postoperative complications. A multicenter randomized prospective analysis would provide additional information of the efficacy and safety of TXA.

Original languageEnglish
JournalSpine
Volume37
Issue number21
DOIs
Publication statusPublished - 2012 Oct 1
Externally publishedYes

Fingerprint

Tranexamic Acid
Spinal Fusion
Scoliosis
Blood Transfusion
Control Groups
Intraoperative Complications
Safety
Therapeutics
Postoperative Hemorrhage
Antifibrinolytic Agents
Operative Time
Hematocrit
Observational Studies
Comorbidity
Hemoglobins
Spine
Retrospective Studies
Demography
Morbidity

Keywords

  • Blood loss
  • Idiopathic scoliosis
  • TXA

ASJC Scopus subject areas

  • Clinical Neurology
  • Orthopedics and Sports Medicine

Cite this

Does the intraoperative tranexamic acid decrease operative blood loss during posterior spinal fusion for treatment of adolescent idiopathic scoliosis? / Yagi, Mitsuru; Hasegawa, Jun; Nagoshi, Narihito; Iizuka, Shingo; Kaneko, Shinjiro; Fukuda, Kentaro; Takemitsu, Masakazu; Shioda, Masanobu; MacHida, Masafumi.

In: Spine, Vol. 37, No. 21, 01.10.2012.

Research output: Contribution to journalArticle

Yagi, Mitsuru ; Hasegawa, Jun ; Nagoshi, Narihito ; Iizuka, Shingo ; Kaneko, Shinjiro ; Fukuda, Kentaro ; Takemitsu, Masakazu ; Shioda, Masanobu ; MacHida, Masafumi. / Does the intraoperative tranexamic acid decrease operative blood loss during posterior spinal fusion for treatment of adolescent idiopathic scoliosis?. In: Spine. 2012 ; Vol. 37, No. 21.
@article{4be4cf61575847b5883bc14af3183259,
title = "Does the intraoperative tranexamic acid decrease operative blood loss during posterior spinal fusion for treatment of adolescent idiopathic scoliosis?",
abstract = "STUDY DESIGN. Retrospective, observational study. OBJECTIVE. To assess the efficacy and safety of tranexamic acid (TXA) in decreasing operative blood loss and the need for transfusion during posterior spinal fusion for the treatment of idiopathic scoliosis in adolescents. SUMMARY OF BACKGROUND DATA.: Blood loss associated with spinal surgery is a common potential cause of morbidity and often requires a blood transfusion, which subjects patients to the known risks of blood transfusion including transmission of diseases. Since the 1990s, intraoperative administration of antifibrinolytics has gained popularity. This study assesses the efficacy and safety of TXA in controlling blood loss during posterior spinal fusion for the treatment of idiopathic scoliosis in adolescents at 1 institution. METHODS. A retrospective comparative analysis of 106 consecutive adolescents undergoing posterior spinal fusion procedures at 1 institution was performed. Patients were analyzed according to treatment group: controls (63) and TXA (43). There were no significant differences in demographic (age, sex, and comorbidities) or surgical traits (surgical time, number of fused vertebrae, preoperative hematocrit and hemoglobin) between the 2 groups. RESULTS. TXA group had significantly less intraoperative blood loss (613 ± 195 mL) than the control group (1079 ± 421 mL; P < 0.001) as well as postoperative blood loss (155 ± 86 mL and 263 ± 105 mL, respectively; P < 0.001). TXA group received significantly less blood during the surgical procedure than the control group (258 ± 246 mL and 377 ± 200 mL, respectively; P < 0.001). There were no major intraoperative complications for any of the treatment groups. CONCLUSION. TXA treatment group lost significantly less blood and received significantly fewer blood transfusions than the control group without significant differences in intra- and postoperative complications. A multicenter randomized prospective analysis would provide additional information of the efficacy and safety of TXA.",
keywords = "Blood loss, Idiopathic scoliosis, TXA",
author = "Mitsuru Yagi and Jun Hasegawa and Narihito Nagoshi and Shingo Iizuka and Shinjiro Kaneko and Kentaro Fukuda and Masakazu Takemitsu and Masanobu Shioda and Masafumi MacHida",
year = "2012",
month = "10",
day = "1",
doi = "10.1097/BRS.0b013e318266b6e5",
language = "English",
volume = "37",
journal = "Spine",
issn = "0362-2436",
publisher = "Lippincott Williams and Wilkins",
number = "21",

}

TY - JOUR

T1 - Does the intraoperative tranexamic acid decrease operative blood loss during posterior spinal fusion for treatment of adolescent idiopathic scoliosis?

AU - Yagi, Mitsuru

AU - Hasegawa, Jun

AU - Nagoshi, Narihito

AU - Iizuka, Shingo

AU - Kaneko, Shinjiro

AU - Fukuda, Kentaro

AU - Takemitsu, Masakazu

AU - Shioda, Masanobu

AU - MacHida, Masafumi

PY - 2012/10/1

Y1 - 2012/10/1

N2 - STUDY DESIGN. Retrospective, observational study. OBJECTIVE. To assess the efficacy and safety of tranexamic acid (TXA) in decreasing operative blood loss and the need for transfusion during posterior spinal fusion for the treatment of idiopathic scoliosis in adolescents. SUMMARY OF BACKGROUND DATA.: Blood loss associated with spinal surgery is a common potential cause of morbidity and often requires a blood transfusion, which subjects patients to the known risks of blood transfusion including transmission of diseases. Since the 1990s, intraoperative administration of antifibrinolytics has gained popularity. This study assesses the efficacy and safety of TXA in controlling blood loss during posterior spinal fusion for the treatment of idiopathic scoliosis in adolescents at 1 institution. METHODS. A retrospective comparative analysis of 106 consecutive adolescents undergoing posterior spinal fusion procedures at 1 institution was performed. Patients were analyzed according to treatment group: controls (63) and TXA (43). There were no significant differences in demographic (age, sex, and comorbidities) or surgical traits (surgical time, number of fused vertebrae, preoperative hematocrit and hemoglobin) between the 2 groups. RESULTS. TXA group had significantly less intraoperative blood loss (613 ± 195 mL) than the control group (1079 ± 421 mL; P < 0.001) as well as postoperative blood loss (155 ± 86 mL and 263 ± 105 mL, respectively; P < 0.001). TXA group received significantly less blood during the surgical procedure than the control group (258 ± 246 mL and 377 ± 200 mL, respectively; P < 0.001). There were no major intraoperative complications for any of the treatment groups. CONCLUSION. TXA treatment group lost significantly less blood and received significantly fewer blood transfusions than the control group without significant differences in intra- and postoperative complications. A multicenter randomized prospective analysis would provide additional information of the efficacy and safety of TXA.

AB - STUDY DESIGN. Retrospective, observational study. OBJECTIVE. To assess the efficacy and safety of tranexamic acid (TXA) in decreasing operative blood loss and the need for transfusion during posterior spinal fusion for the treatment of idiopathic scoliosis in adolescents. SUMMARY OF BACKGROUND DATA.: Blood loss associated with spinal surgery is a common potential cause of morbidity and often requires a blood transfusion, which subjects patients to the known risks of blood transfusion including transmission of diseases. Since the 1990s, intraoperative administration of antifibrinolytics has gained popularity. This study assesses the efficacy and safety of TXA in controlling blood loss during posterior spinal fusion for the treatment of idiopathic scoliosis in adolescents at 1 institution. METHODS. A retrospective comparative analysis of 106 consecutive adolescents undergoing posterior spinal fusion procedures at 1 institution was performed. Patients were analyzed according to treatment group: controls (63) and TXA (43). There were no significant differences in demographic (age, sex, and comorbidities) or surgical traits (surgical time, number of fused vertebrae, preoperative hematocrit and hemoglobin) between the 2 groups. RESULTS. TXA group had significantly less intraoperative blood loss (613 ± 195 mL) than the control group (1079 ± 421 mL; P < 0.001) as well as postoperative blood loss (155 ± 86 mL and 263 ± 105 mL, respectively; P < 0.001). TXA group received significantly less blood during the surgical procedure than the control group (258 ± 246 mL and 377 ± 200 mL, respectively; P < 0.001). There were no major intraoperative complications for any of the treatment groups. CONCLUSION. TXA treatment group lost significantly less blood and received significantly fewer blood transfusions than the control group without significant differences in intra- and postoperative complications. A multicenter randomized prospective analysis would provide additional information of the efficacy and safety of TXA.

KW - Blood loss

KW - Idiopathic scoliosis

KW - TXA

UR - http://www.scopus.com/inward/record.url?scp=84866998607&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84866998607&partnerID=8YFLogxK

U2 - 10.1097/BRS.0b013e318266b6e5

DO - 10.1097/BRS.0b013e318266b6e5

M3 - Article

VL - 37

JO - Spine

JF - Spine

SN - 0362-2436

IS - 21

ER -